E. Bleickardt

发表

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

M. Beksac, K. Anderson, M. Dimopoulos, 2017, British journal of haematology.

Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)

H. Kantarjian, S. Agrawal, A. Hochhaus, 2008 .

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Matthew J. Frigault, R. Chawla, S. Grupp, 2020, Blood advances.

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer

A. Baruchel, Abraham I. Bassan, G. Vassal, 2021, European Journal of Cancer.

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value

J. Radich, H. Kantarjian, J. Lipton, 2009, Leukemia.

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

C. Sawyers, R. Paquette, N. Shah, 2006 .

Camptothecin and taxane regimens for small-cell lung cancer.

J. Murren, E. Bleickardt, M. Kwong, 2002, Oncology.

Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer

D. Zelterman, A. Argiris, B. Burtness, 2002, Cancer biology & therapy.

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Manuel Ayala, Ricardo Pasquini, Jorge Cortes, 2010, The New England journal of medicine.

Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034

H. Kantarjian, P. Rousselot, A. Hochhaus, 2007 .

Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study.

C. Sawyers, J. Cortes, P. Rousselot, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

C. Sawyers, M. Talpaz, P. Rousselot, 2005 .

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Susan O'Brien, Jorge Cortes, John Nicoll, 2006, The New England journal of medicine.

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

S. Jagannath, A. Jakubowiak, S. Lonial, 2015, The Lancet. Haematology.

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

H. Kantarjian, P. Rousselot, A. Hochhaus, 2006 .

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Jessica Katz, Hermann Einsele, Paul Richardson, 2015, The New England journal of medicine.

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

T. Mori, M. Taniwaki, S. Iida, 2017, Blood Cancer Journal.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

S. Jagannath, R. Vij, J. Kaufman, 2015, Clinical lymphoma, myeloma & leukemia.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, S. Lonial, 2014 .

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

K. Davis, S. Rives, A. Baruchel, 2018, Blood.

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Taosheng Chen, C. Sawyers, H. Kantarjian, 2005 .

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

R. Chawla, M. Perales, S. Nikiforow, 2019, Blood.

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.

Christopher Weier, C. Sawyers, N. Shah, 2008, Cancer cell.

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

R. Chawla, S. Grupp, S. Nikiforow, 2019, Blood.

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

H. Kantarjian, J. Cortes, N. Shah, 2009, Cancer.

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

P. Erben, A. Hochhaus, T. Ernst, 2007 .

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Michael D. Robbins, A. Jakubowiak, B. Pégourié, 2016, Blood.

Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

D. Lebwohl, T. Taran, M. Leung, 2019, Current Hematologic Malignancy Reports.

Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study

Michael D. Robbins, S. Iida, T. Chou, 2017, International Journal of Hematology.

Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).

M. Baccarani, H. Kantarjian, J. Lipton, 2007 .

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Martin C. Müller, J. Radich, J. Lipton, 2008 .

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

M. Baccarani, G. Rosti, J. Cortes, 2008 .

Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R

H. Kantarjian, R. Paquette, P. Rousselot, 2008 .

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

H. Kantarjian, P. Rousselot, N. Shah, 2007 .

Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma

A. Oriol, J. San-Miguel, J. Bladé, 2016, British journal of haematology.

Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

S. Jagannath, A. Jakubowiak, S. Lonial, 2013 .

National Oncology Forum: perspectives for the year 2000.

V. Devita, E. Bleickardt, 2001, Cancer journal.

Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial

K. Davis, S. Rives, A. Baruchel, 2019, Biology of Blood and Marrow Transplantation.

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

S. Jagannath, R. Vij, J. Kaufman, 2014 .

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

M. Dimopoulos, A. Palumbo, S. Lonial, 2015 .

A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

A. Jakubowiak, B. Pégourié, J. Laubach, 2015 .

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

H. Kantarjian, J. Cortes, N. Shah, 2009, Cancer.

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.